BiomX Reported Earnings

BiomX (PHGE) reported a loss of $0.37 per share on revenue of $0.33 million for the second quarter ended June 2026. .

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as inflammatory bowel disease, primary sclerosing cholangitis, cystic fibrosis, atopic dermatitis and colorectal cancer.